Pasithea Therapeutics (KTTA) Liabilities and Shareholders Equity (2021 - 2024)
Historic Liabilities and Shareholders Equity for Pasithea Therapeutics (KTTA) over the last 4 years, with Q3 2024 value amounting to $18.6 million.
- Pasithea Therapeutics' Liabilities and Shareholders Equity fell 3920.74% to $18.6 million in Q3 2024 from the same period last year, while for Dec 2024 it was $58.7 million, marking a year-over-year decrease of 5713.69%. This contributed to the annual value of $26.1 million for FY2023, which is 4219.39% down from last year.
- According to the latest figures from Q3 2024, Pasithea Therapeutics' Liabilities and Shareholders Equity is $18.6 million, which was down 3920.74% from $17.7 million recorded in Q2 2024.
- Pasithea Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $53.3 million during Q4 2021, with a 5-year trough of $17.7 million in Q2 2024.
- Its 4-year average for Liabilities and Shareholders Equity is $36.1 million, with a median of $38.1 million in 2023.
- Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first skyrocketed by 13575.38% in 2022, then crashed by 5369.94% in 2024.
- Quarter analysis of 4 years shows Pasithea Therapeutics' Liabilities and Shareholders Equity stood at $53.3 million in 2021, then decreased by 15.27% to $45.2 million in 2022, then plummeted by 42.19% to $26.1 million in 2023, then fell by 28.64% to $18.6 million in 2024.
- Its Liabilities and Shareholders Equity was $18.6 million in Q3 2024, compared to $17.7 million in Q2 2024 and $22.4 million in Q1 2024.